drugset / Trial / NCT02325011

An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.

NCT02325011

Phase 1 Completed 14 enrolled Jazz Pharmaceuticals
RandomizedCrossoverOpen-labelBasic science

Summary

The study aims to evaluate the effect of fluconazole on the pharmacokinetic (PK) profile of a single oromucosal dose of Sativex® (i.e. how the body absorbs, distributes, metabolises and excretes the drug) in healthy subjects with a history of cannabis use. The primary clinical hypothesis is that no drug-drug interaction between Sativex® and fluconazole will be detected as effects on PK parameters of Sativex®, when both are administered to healthy human volunteers who have experience using cannabis. The study additionally aims to evaluate the safety and tolerability of an oromucosal dose of Sativex® in subjects when given concurrently with fluconazole.

Timeline

Start
2014-11
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule 200 mg
Subject Nabiximols Other / unclassified 10 mg Other
Subject Nabiximols Other / unclassified 10.8 mg Other

Indications

No indication recorded.